<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04144842</url>
  </required_header>
  <id_info>
    <org_study_id>A-19-1017-C-01</org_study_id>
    <nct_id>NCT04144842</nct_id>
  </id_info>
  <brief_title>ATOR-1017 First-in-human Study</brief_title>
  <official_title>A First-in-human, Multicenter, Open-label, Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1017</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alligator Bioscience AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alligator Bioscience AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the safety and tolerability of increasing doses of
      ATOR-1017 when administered as repeated intravenous infusions to patients with advanced
      and/or refractory solid malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability: Adverse events (AEs) assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 5.0</measure>
    <time_frame>From start of study until 28 days after last dose</time_frame>
    <description>Number of participants with treatment-related AEs assessed by CTCAE v 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability: Dose-limiting toxicities (DLTs)</measure>
    <time_frame>From first dose of ATOR-1017 (Day 1) until Day 21</time_frame>
    <description>Number of participants with DLTs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum observed serum concentration of ATOR-1017 (Cmax)</measure>
    <time_frame>From start of study until end of study (28-56 days after last dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time to Cmax</measure>
    <time_frame>From start of study until end of study (28-56 days after last dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the ATOR-1017 serum concentration-time curve (AUC)</measure>
    <time_frame>From start of study until end of study (28-56 days after last dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Anti-drug antibody (ADA) titer in serum</measure>
    <time_frame>From start of study until end of study (28-56 days after last dose)</time_frame>
    <description>Levels of antibodies to ATOR-1017 will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy: Anti-tumor activity assessed by response evaluation criteria in solid tumors for immune-based therapeutics (iRECIST)</measure>
    <time_frame>From start of study until end of study (28-56 days after last dose)</time_frame>
    <description>Computed tomography (CT) scans of tumors will be evaluated according to iRECIST</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>ATOR-1017</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATOR-1017 administered by intravenous infusions every 3 weeks until confirmed progressive disease, clear clinical deterioration, unacceptable toxicity or withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATOR-1017</intervention_name>
    <description>ATOR-1017 is a human monoclonal antibody targeting 4-1BB (CD137)</description>
    <arm_group_label>ATOR-1017</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

        A patient is eligible to be included in the study if all the following criteria apply:

          -  Has a diagnosis of advanced and/or refractory solid malignancy (histologically or
             cytologically documented)

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Has a minimum of one measurable tumor lesion

          -  Has acceptable hematologic and clinical chemistry laboratory values

        Major Exclusion Criteria:

        A patient is excluded if any of the following criteria apply:

          -  Has not recovered from AEs to at least grade 1 by CTCAE version 5.0 due to prior
             anti-cancer medications

          -  Has symptomatic, steroid-dependent or progressive brain metastasis/metastases

          -  Has a history of another primary malignancy, except for: a) Malignancy treated with
             curative intent and with no known active disease within 2 years prior to first dose of
             ATOR-1017, b) Adequately treated non-invasive basal skin cancer or squamous cell skin
             carcinoma, c) Adequately treated uterine cervical cancer stage 1B or less

          -  Has an autoimmune disorder requiring immune modulating treatment during the last 2
             years

          -  Receives treatment with systemic immunosuppressant medication (except for inhaled and
             low dose systemic corticosteroids, i.e. ≤10 mg prednisolone or equivalent per day)

          -  Is a female patient who is pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Russell, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Alligator Bioscience AB</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustav Ullenhag, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, Uppsala University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip Van Der Veen</last_name>
    <phone>+44 (0) 1293 510319</phone>
    <email>PVanDerVeen@Theradex.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emma Elison</last_name>
    <email>Eme@AlligatorBioscience.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Oncology, Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Carneiro, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fas 1-enheten, Centrum för Kliniska Cancerstudier, Karolinska Universitetssjukhuset</name>
      <address>
        <city>Solna</city>
        <zip>SE-171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Yachnin, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustav Ullenhag, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

